FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291036716> ?p ?o ?g. }

• W4291036716 endingPage "e10214" @default.
• W4291036716 startingPage "e10214" @default.
• W4291036716 abstract "BackgroundFor patients who treated with tacrolimus after kidney transplant, therapeutic drug monitoring is essential to improve their prognosis. However, previous detection methods have limitations, such as the overestimation and unacceptable bias in the immunoassays. Precision medicine has been challenged. The liquid chromatography-tandem mass spectrometry (LC-MS/MS) method is recognized as the gold standard due to its accuracy and specificity, but lack of throughput and complex process limits its clinical application. Therefore, an accurate, simple and high throughput method for tacrolimus monitoring is needed for clinical practice.MethodsA modified LC-MS/MS method was introduced and validated. Whole blood samples were prepared by a one-step protein precipitation method. Chromatographic separation was achieved using a Phenomenex Kinetex 2.6 μm XB-C18 2.1 × 50 mm column with a total run time of 3.5 min to avoid matrix effect. An electrospray ionization source (ESI) was used in positive ion multiple reaction monitoring (MRM) mode for mass spectrometric detection. In order to protect the mass spectrometer, only part of the sample after LC separation was allowed to enter the mass spectrum, through a two HPLC systems coupled one mass spectrometry design. In this way, the instrument throughput is also improved and realizing the detection of 2 samples within 3.5 min and carried out a shorter analyzing time for each sample of 1.75 min. Additionally, we calculated tacrolimus-intrapatient variant (Tac-IPV) based on this modified method and assessed the prognostic value of Tac-IPV in Chinese kidney transplant patients.ResultsThe LC-MS/MS was modified by streamlining the procedure and increasing the throughput. The method proved to be accurate and reproducible with all performance parameters suitably meeting the clinical requirements over a calibration ranged from 0.37 to 42.90 ng/mL. Parameters such as linearity, limit of quantification (LoQ) and dilution integrity were validated with a clinical reportable range from 0.37 to 343.20 ng/mL, which was particularly useful for high drug concentrations patients (rare but very serious). Both cross-contamination and matrix effects were negligible. Clinical data of 83 patients showed that Tac-IPV was associated with poor kidney transplant outcome in Chinese (Hazard Ratio (HR) = 3.96, 4.75; 95% Cl: 1.10–14.21, 1.23–18.36; P < 0.05).ConclusionsThis modified LC-MS/MS method possessed high throughput and simple sample preparation, allowing it to meet daily clinical needs. At the same time, Tac-IPV based on this modified LC-MS/MS had excellent prognostic value in kidney transplantation. These advantages have great significance for the individualized treatment of Chinese kidney transplant patients and broad application of Tac-IPV." @default.
• W4291036716 created "2022-08-13" @default.
• W4291036716 creator A5003416636 @default.
• W4291036716 creator A5007498164 @default.
• W4291036716 creator A5015668008 @default.
• W4291036716 creator A5020873750 @default.
• W4291036716 creator A5029942082 @default.
• W4291036716 creator A5030006523 @default.
• W4291036716 creator A5031616500 @default.
• W4291036716 creator A5034291484 @default.
• W4291036716 creator A5045525981 @default.
• W4291036716 creator A5058111140 @default.
• W4291036716 creator A5063120599 @default.
• W4291036716 creator A5065273078 @default.
• W4291036716 creator A5067810006 @default.
• W4291036716 creator A5077985811 @default.
• W4291036716 creator A5085331622 @default.
• W4291036716 creator A5090299401 @default.
• W4291036716 date "2022-08-01" @default.
• W4291036716 modified "2023-10-16" @default.
• W4291036716 title "A modified LC-MS/MS method for the detection of whole blood tacrolimus and its clinical value in Chinese kidney transplant patients" @default.
• W4291036716 cites W1477512010 @default.
• W4291036716 cites W1996001672 @default.
• W4291036716 cites W2064477213 @default.
• W4291036716 cites W2071190197 @default.
• W4291036716 cites W2109138494 @default.
• W4291036716 cites W2131745220 @default.
• W4291036716 cites W2142102659 @default.
• W4291036716 cites W2216452883 @default.
• W4291036716 cites W2300477263 @default.
• W4291036716 cites W2342542291 @default.
• W4291036716 cites W2405408370 @default.
• W4291036716 cites W2599884304 @default.
• W4291036716 cites W2727941093 @default.
• W4291036716 cites W2734192514 @default.
• W4291036716 cites W2751083476 @default.
• W4291036716 cites W2752848998 @default.
• W4291036716 cites W2796789589 @default.
• W4291036716 cites W2896175984 @default.
• W4291036716 cites W2898261508 @default.
• W4291036716 cites W2945746052 @default.
• W4291036716 cites W2965511964 @default.
• W4291036716 cites W2968363366 @default.
• W4291036716 cites W2969538871 @default.
• W4291036716 cites W2970478324 @default.
• W4291036716 cites W3023620746 @default.
• W4291036716 cites W3107480166 @default.
• W4291036716 cites W3120113640 @default.
• W4291036716 cites W3144392949 @default.
• W4291036716 cites W3202421714 @default.
• W4291036716 cites W3212176386 @default.
• W4291036716 doi "https://doi.org/10.1016/j.heliyon.2022.e10214" @default.
• W4291036716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36042743" @default.
• W4291036716 hasPublicationYear "2022" @default.
• W4291036716 type Work @default.
• W4291036716 citedByCount "2" @default.
• W4291036716 countsByYear W42910367162023 @default.
• W4291036716 crossrefType "journal-article" @default.
• W4291036716 hasAuthorship W4291036716A5003416636 @default.
• W4291036716 hasAuthorship W4291036716A5007498164 @default.
• W4291036716 hasAuthorship W4291036716A5015668008 @default.
• W4291036716 hasAuthorship W4291036716A5020873750 @default.
• W4291036716 hasAuthorship W4291036716A5029942082 @default.
• W4291036716 hasAuthorship W4291036716A5030006523 @default.
• W4291036716 hasAuthorship W4291036716A5031616500 @default.
• W4291036716 hasAuthorship W4291036716A5034291484 @default.
• W4291036716 hasAuthorship W4291036716A5045525981 @default.
• W4291036716 hasAuthorship W4291036716A5058111140 @default.
• W4291036716 hasAuthorship W4291036716A5063120599 @default.
• W4291036716 hasAuthorship W4291036716A5065273078 @default.
• W4291036716 hasAuthorship W4291036716A5067810006 @default.
• W4291036716 hasAuthorship W4291036716A5077985811 @default.
• W4291036716 hasAuthorship W4291036716A5085331622 @default.
• W4291036716 hasAuthorship W4291036716A5090299401 @default.
• W4291036716 hasBestOaLocation W42910367161 @default.
• W4291036716 hasConcept C113196181 @default.
• W4291036716 hasConcept C126322002 @default.
• W4291036716 hasConcept C1621761 @default.
• W4291036716 hasConcept C162356407 @default.
• W4291036716 hasConcept C185592680 @default.
• W4291036716 hasConcept C2778576202 @default.
• W4291036716 hasConcept C2909675724 @default.
• W4291036716 hasConcept C2911091166 @default.
• W4291036716 hasConcept C31827203 @default.
• W4291036716 hasConcept C40684141 @default.
• W4291036716 hasConcept C43617362 @default.
• W4291036716 hasConcept C64489805 @default.
• W4291036716 hasConcept C71043704 @default.
• W4291036716 hasConcept C71924100 @default.
• W4291036716 hasConcept C74774607 @default.
• W4291036716 hasConceptScore W4291036716C113196181 @default.
• W4291036716 hasConceptScore W4291036716C126322002 @default.
• W4291036716 hasConceptScore W4291036716C1621761 @default.
• W4291036716 hasConceptScore W4291036716C162356407 @default.
• W4291036716 hasConceptScore W4291036716C185592680 @default.
• W4291036716 hasConceptScore W4291036716C2778576202 @default.
• W4291036716 hasConceptScore W4291036716C2909675724 @default.
• W4291036716 hasConceptScore W4291036716C2911091166 @default.

• next